{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:09:00Z","timestamp":1790759340769,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012952","name":"Universit\u00e9 Grenoble Alpes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012952","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bcp.2020.114039","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T18:47:39Z","timestamp":1589568459000},"page":"114039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Targeting the spliceosome machinery: A new therapeutic axis in cancer?"],"prefix":"10.1016","volume":"189","author":[{"given":"Beatrice","family":"Eymin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cell.2019.12.011","article-title":"SnapShot: splicing alterations in cancer","volume":"180","author":"Rahman","year":"2020","journal-title":"Cell"},{"issue":"46","key":"10.1016\/j.bcp.2020.114039_b0010","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1038\/onc.2013.533","article-title":"Hallmarks of alternative splicing in cancer","volume":"33","author":"Oltean","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molmed.2015.11.005","article-title":"Small molecule modulators of Pre-mRNA splicing in cancer therapy","volume":"22","author":"Salton","year":"2016","journal-title":"Trends Mol. Med."},{"issue":"6894","key":"10.1016\/j.bcp.2020.114039_b0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/418236a","article-title":"Alternative pre-mRNA splicing and proteome expansion in metazoans","volume":"418","author":"Maniatis","year":"2002","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1097-2765(03)00270-3","article-title":"Pre-mRNA splicing: awash in a sea of proteins","volume":"12","author":"Jurica","year":"2003","journal-title":"Mol. Cell."},{"key":"10.1016\/j.bcp.2020.114039_b0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-biochem-060614-034316","article-title":"Mechanisms and regulation of alternative pre-mRNA splicing","volume":"84","author":"Lee","year":"2015","journal-title":"Annu. Rev. Biochem."},{"issue":"7189","key":"10.1016\/j.bcp.2020.114039_b0035","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nature06842","article-title":"Isolation of an active step I spliceosome and composition of its RNP core","volume":"452","author":"Bessonov","year":"2008","journal-title":"Nature"},{"issue":"5601","key":"10.1016\/j.bcp.2020.114039_b0040","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1126\/science.1077783","article-title":"Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome","volume":"298","author":"Makarov","year":"2002","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0045","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0968-0004(00)01549-8","article-title":"Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases","volume":"25","author":"Blencowe","year":"2000","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molcel.2006.05.018","article-title":"General and specific functions of exonic splicing silencers in splicing control","volume":"23","author":"Wang","year":"2006","journal-title":"Mol. Cell."},{"issue":"12","key":"10.1016\/j.bcp.2020.114039_b0055","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/ng.259","article-title":"Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing","volume":"40","author":"Pan","year":"2008","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.bcp.2020.114039_b0060","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrm.2017.27","article-title":"Alternative splicing as a regulator of development and tissue identity","volume":"18","author":"Baralle","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0065","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ceb.2005.04.014","article-title":"Promoter usage and alternative splicing","volume":"17","author":"Kornblihtt","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"issue":"24","key":"10.1016\/j.bcp.2020.114039_b0070","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1093\/nar\/26.24.5568","article-title":"Co-transcriptional commitment to alternative splice site selection","volume":"26","author":"Roberts","year":"1998","journal-title":"Nucleic Acids Res."},{"issue":"5968","key":"10.1016\/j.bcp.2020.114039_b0075","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1184208","article-title":"Regulation of alternative splicing by histone modifications","volume":"327","author":"Luco","year":"2010","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bcp.2020.114039_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002717","article-title":"Psip1\/Ledgf p52 binds methylated histone H3K36 and splicing factors and contributes to the regulation of alternative splicing","volume":"8","author":"Pradeepa","year":"2012","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1083\/jcb.201510032","article-title":"Defective control of pre-messenger RNA splicing in human disease","volume":"212","author":"Chabot","year":"2016","journal-title":"J. Cell Biol."},{"issue":"7","key":"10.1016\/j.bcp.2020.114039_b0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrc.2016.51","article-title":"RNA splicing factors as oncoproteins and tumour suppressors","volume":"16","author":"Dvinge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"10.1016\/j.bcp.2020.114039_b0095","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1093\/hmg\/ddr370","article-title":"Increased levels of noisy splicing in cancers, but not for oncogene-derived transcripts","volume":"20","author":"Chen","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2020.114039_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bcp.2020.114039_b0105","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMcibr1814237","article-title":"Alternative splicing in tumors \u2013 a path to immunogenicity?","volume":"380","author":"Slansky","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bcp.2020.114039_b0110","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/ng.3414","article-title":"Intron retention is a widespread mechanism of tumor-suppressor inactivation","volume":"47","author":"Jung","year":"2015","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bcp.2020.114039_b0115","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cell.2014.01.051","article-title":"Synonymous mutations frequently act as driver mutations in human cancers","volume":"156","author":"Supek","year":"2014","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bcp.2020.114039_b0120","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1261\/rna.057919.116","article-title":"Splicing-factor alterations in cancers","volume":"22","author":"Anczukow","year":"2016","journal-title":"RNA"},{"issue":"6","key":"10.1016\/j.bcp.2020.114039_b0125","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1101\/gr.199935.115","article-title":"Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks","volume":"26","author":"Sebestyen","year":"2016","journal-title":"Genome Res."},{"issue":"10","key":"10.1016\/j.bcp.2020.114039_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046539","article-title":"Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma","volume":"7","author":"Gout","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2020.114039_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165687","article-title":"Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma","volume":"1866","author":"Soto","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"5","key":"10.1016\/j.bcp.2020.114039_b0140","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","article-title":"Cancer-associated SF3B1 hotspot mutations induce cryptic 3' splice site selection through use of a different branch point","volume":"13","author":"Darman","year":"2015","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0145","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","article-title":"Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation","volume":"30","author":"Obeng","year":"2016","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bcp.2020.114039_b0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"7780","key":"10.1016\/j.bcp.2020.114039_b0155","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-019-1651-z","article-title":"The U1 spliceosomal RNA is recurrently mutated in multiple cancers","volume":"574","author":"Shuai","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114039_b0160","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-1650-0","article-title":"Recurrent non-coding U1-snRNA mutations drive cryptic splicing in Shh medulloblastoma","author":"Suzuki","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2020.114039_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1381","article-title":"Modulating splicing with small molecular inhibitors of the spliceosome","volume":"8","author":"Effenberger","year":"2017","journal-title":"Wiley Interdiscip. Rev. RNA"},{"issue":"24","key":"10.1016\/j.bcp.2020.114039_b0170","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1073\/pnas.0409829102","article-title":"Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors","volume":"102","author":"Soret","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"2","key":"10.1016\/j.bcp.2020.114039_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.07.003","article-title":"Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation","volume":"36","author":"Fong","year":"2019","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bcp.2020.114039_b0180","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nm.4165","article-title":"Therapeutic targeting of splicing in cancer","volume":"22","author":"Lee","year":"2016","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2020.114039_b0185","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41573-019-0042-3","article-title":"Targeting mRNA processing as an anticancer strategy","volume":"19","author":"Desterro","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6336","key":"10.1016\/j.bcp.2020.114039_b0190","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bcp.2020.114039_b0195","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41589-019-0378-3","article-title":"Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15","volume":"16","author":"Faust","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2020.114039_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.09.079","article-title":"Aryl sulfonamides degrade RBM39 and RBM23 by recruitment to CRL4-DCAF15","volume":"29","author":"Ting","year":"2019","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-binding protein network in acute myeloid leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.bcp.2020.114039_b0215","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1021\/acs.jmedchem.7b00461","article-title":"Discovery of allosteric inhibitors targeting the spliceosomal RNA helicase Brr2","volume":"60","author":"Iwatani-Yoshihara","year":"2017","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2020.114039_b0220","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1128\/MCB.05788-11","article-title":"A quantitative high-throughput in vitro splicing assay identifies inhibitors of spliceosome catalysis","volume":"32","author":"Berg","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2020.114039_b0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.trsl.2019.07.001","article-title":"Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer","volume":"212","author":"Jimenez-Vacas","year":"2019","journal-title":"Transl. Res."},{"issue":"20","key":"10.1016\/j.bcp.2020.114039_b0230","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-18-3965","article-title":"SF3B2-mediated RNA splicing drives human prostate cancer progression","volume":"79","author":"Kawamura","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114039_b0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ebiom.2018.12.025","article-title":"Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma","volume":"39","author":"Sciarrillo","year":"2019","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0240","doi-asserted-by":"crossref","first-page":"352","DOI":"10.18632\/oncotarget.26564","article-title":"Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy","volume":"10","author":"Yamano","year":"2019","journal-title":"Oncotarget"},{"issue":"26","key":"10.1016\/j.bcp.2020.114039_b0245","doi-asserted-by":"crossref","first-page":"22734","DOI":"10.18632\/oncotarget.4212","article-title":"The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia","volume":"6","author":"Xargay-Torrent","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0250","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tibs.2014.01.003","article-title":"DNA damage: RNA-binding proteins protect from near and far","volume":"39","author":"Dutertre","year":"2014","journal-title":"Trends Biochem. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0255","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/ijms17030310","article-title":"Roles of RNA-binding proteins in DNA damage response","volume":"17","author":"Kai","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2020.114039_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2017.07.002","article-title":"Introns protect eukaryotic genomes from transcription-associated genetic instability","volume":"67","author":"Bonnet","year":"2017","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2017.12.029","article-title":"The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations","volume":"69","author":"Chen","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2020.114039_b0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.dnarep.2018.04.003","article-title":"Multiple roles of the splicing complex SF3B in DNA end resection and homologous recombination","volume":"66\u201367","author":"Prados-Carvajal","year":"2018","journal-title":"DNA Repair (Amst)"},{"issue":"12","key":"10.1016\/j.bcp.2020.114039_b0275","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2016.70","article-title":"The spliceosome U2 snRNP factors promote genome stability through distinct mechanisms; transcription of repair factors and R-loop processing","volume":"5","author":"Tanikawa","year":"2016","journal-title":"Oncogenesis"},{"issue":"10","key":"10.1016\/j.bcp.2020.114039_b0280","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/cdd.2016.58","article-title":"Splicing controls the ubiquitin response during DNA double-strand break repair","volume":"23","author":"Pederiva","year":"2016","journal-title":"Cell Death Differ."},{"issue":"55","key":"10.1016\/j.bcp.2020.114039_b0285","doi-asserted-by":"crossref","first-page":"93319","DOI":"10.18632\/oncotarget.21555","article-title":"PRPF8 is important for BRCA1-mediated homologous recombination","volume":"8","author":"Onyango","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0290","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1038\/s41467-018-06677-1","article-title":"DHX9 helicase promotes R-loop formation in cells with impaired RNA splicing","volume":"9","author":"Chakraborty","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13073-018-0557-y","article-title":"Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells","volume":"10","author":"Anufrieva","year":"2018","journal-title":"Genome Med."},{"issue":"2","key":"10.1016\/j.bcp.2020.114039_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172209","article-title":"Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status","volume":"12","author":"Suda","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0305","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1042\/BJ20081501","article-title":"The SR protein family of splicing factors: master regulators of gene expression","volume":"417","author":"Long","year":"2009","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.bcp.2020.114039_b0310","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ccr.2011.10.016","article-title":"WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing","volume":"20","author":"Amin","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2020.114039_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104777","article-title":"Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells","volume":"65","author":"Siqueira","year":"2020","journal-title":"Toxicol. In Vitro"},{"issue":"4","key":"10.1016\/j.bcp.2020.114039_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2018.01.013","article-title":"SRPKIN-1: a covalent SRPK1\/2 Inhibitor that potently converts VEGF from pro-angiogenic to anti-angiogenic isoform","volume":"25","author":"Hatcher","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0325","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1021\/acschembio.6b01048","article-title":"Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease","volume":"12","author":"Batson","year":"2017","journal-title":"ACS Chem. Biol."},{"issue":"33","key":"10.1016\/j.bcp.2020.114039_b0330","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1038\/onc.2014.360","article-title":"Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer","volume":"34","author":"Mavrou","year":"2015","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bcp.2020.114039_b0335","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","article-title":"A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia","volume":"17","author":"Tzelepis","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0340","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1038\/s41467-018-07620-0","article-title":"SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4","volume":"9","author":"Tzelepis","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0345","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.molcel.2014.03.007","article-title":"Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt","volume":"54","author":"Wang","year":"2014","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116929","article-title":"Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing","volume":"10","author":"Araki","year":"2015","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.bcp.2020.114039_b0355","doi-asserted-by":"crossref","first-page":"24246","DOI":"10.1074\/jbc.M314298200","article-title":"Manipulation of alternative splicing by a newly developed inhibitor of Clks","volume":"279","author":"Muraki","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2020.114039_b0360","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708289","article-title":"Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability","volume":"10","author":"Iwai","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2020.114039_b0365","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2019.09.009","article-title":"The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models","volume":"473","author":"Tam","year":"2020","journal-title":"Cancer Lett."},{"issue":"30","key":"10.1016\/j.bcp.2020.114039_b0370","doi-asserted-by":"crossref","first-page":"11329","DOI":"10.1073\/pnas.0604616103","article-title":"Utilization of host SR protein kinases and RNA-splicing machinery during viral replication","volume":"103","author":"Fukuhara","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"6","key":"10.1016\/j.bcp.2020.114039_b0375","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nm.4097","article-title":"Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins","volume":"22","author":"Lee","year":"2016","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2020.114039_b0380","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1101\/gad.2014311","article-title":"Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A","volume":"25","author":"Corrionero","year":"2011","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0385","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41467-018-08150-5","article-title":"Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators","volume":"10","author":"Aird","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0390","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.molcel.2013.06.012","article-title":"Competition between pre-mRNAs for the splicing machinery drives global regulation of splicing","volume":"51","author":"Munding","year":"2013","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0395","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/s41467-017-02007-z","article-title":"Molecular basis of differential 3' splice site sensitivity to anti-tumor drugs targeting U2 snRNP","volume":"8","author":"Vigevani","year":"2017","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bcp.2020.114039_b0400","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acschembio.6b00399","article-title":"Selectivity in small molecule splicing modulation","volume":"11","author":"Kumar","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"22","key":"10.1016\/j.bcp.2020.114039_b0405","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors","volume":"19","author":"Eskens","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2020.114039_b0410","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","article-title":"A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors","volume":"32","author":"Hong","year":"2014","journal-title":"Invest. New Drugs"},{"issue":"6","key":"10.1016\/j.bcp.2020.114039_b0415","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1021\/cb100356k","article-title":"Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing","volume":"6","author":"Fan","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2020.114039_b0420","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1038\/ncomms8103","article-title":"Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing","volume":"6","author":"Salton","year":"2015","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2020.114039_b0425","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B\u20138800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.114039_b0430","doi-asserted-by":"crossref","first-page":"14060","DOI":"10.1038\/ncomms14060","article-title":"Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome","volume":"8","author":"Shirai","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2020.114039_b0435","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23268","article-title":"Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability","volume":"6","author":"Paolella","year":"2017","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.bcp.2020.114039_b0440","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cell.2012.07.023","article-title":"Cancer vulnerabilities unveiled by genomic loss","volume":"150","author":"Nijhawan","year":"2012","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.bcp.2020.114039_b0445","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1038\/s41388-019-0711-z","article-title":"High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome","volume":"38","author":"Blijlevens","year":"2019","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.bcp.2020.114039_b0450","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1158\/1535-7163.MCT-17-0461","article-title":"Basal-A triple-negative breast cancer cells selectively rely on RNA splicing for survival","volume":"16","author":"Chan","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"7569","key":"10.1016\/j.bcp.2020.114039_b0455","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature14985","article-title":"The spliceosome is a therapeutic vulnerability in MYC-driven cancer","volume":"525","author":"Hsu","year":"2015","journal-title":"Nature"},{"issue":"7279","key":"10.1016\/j.bcp.2020.114039_b0460","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nature08697","article-title":"HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer","volume":"463","author":"David","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2020.114039_b0465","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.celrep.2011.12.001","article-title":"Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC","volume":"1","author":"Das","year":"2012","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.bcp.2020.114039_b0470","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1073\/pnas.1915975117","article-title":"Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers","volume":"117","author":"Phillips","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"7558","key":"10.1016\/j.bcp.2020.114039_b0475","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature14351","article-title":"MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis","volume":"523","author":"Koh","year":"2015","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.bcp.2020.114039_b0480","doi-asserted-by":"crossref","first-page":"23029","DOI":"10.18632\/oncotarget.25196","article-title":"Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity","volume":"9","author":"Hepburn","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bcp.2020.114039_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2018.12.008","article-title":"Genetic screens reveal FEN1 and APEX2 as BRCA2 synthetic lethal targets","volume":"73","author":"Mengwasser","year":"2019","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.bcp.2020.114039_b0490","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of 'BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"19","key":"10.1016\/j.bcp.2020.114039_b0495","article-title":"Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies","volume":"3","author":"Ten Hacken","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.bcp.2020.114039_b0500","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/leu.2015.286","article-title":"The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1","volume":"30","author":"Larrayoz","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bcp.2020.114039_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2017.10.034","article-title":"The output of protein-coding genes shifts to circular RNAs when the pre-mRNA processing machinery is limiting","volume":"68","author":"Liang","year":"2017","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bcp.2020.114039_b0510","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/s41467-019-09523-0","article-title":"Specific inhibition of splicing factor activity by decoy RNA oligonucleotides","volume":"10","author":"Denichenko","year":"2019","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bcp.2020.114039_b0515","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nbt.4239","article-title":"Intron retention is a source of neoepitopes in cancer","volume":"36","author":"Smart","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.bcp.2020.114039_b0520","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110458","article-title":"Aberrant RNA splicing in cancer and drug resistance","volume":"10","author":"Wang","year":"2018","journal-title":"Cancers (Basel)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:08:37Z","timestamp":1762096117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220302732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":104,"alternative-id":["S0006295220302732"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114039","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the spliceosome machinery: A new therapeutic axis in cancer?","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114039"}}